Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Howard Hughes Holdings Inc. Announces Dates and Times for 2025 Fourth Quarter Earnings Release and Conference Call
-
SchoolAI Research Challenges Fears About AI in the Classroom with Evidence From 23,000 Teacher-Created Lessons
-
Microchip Releases Custom Firmware For NVIDIA DGX Spark For Its MEC1723 Embedded Controllers
-
Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights
-
Beacon Therapeutics Announces Closing of Oversubscribed Series C Financing for Over $75 Million
-
VarmX and Rentschler Biopharma partner to advance novel coagulation therapy toward Phase 3 and commercialization
-
Lexeo Therapeutics Announces Research Collaboration to Explore Targeted Cardiac Delivery of AAV Gene Therapy
-
Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria
-
Opus Genetics Highlights 2025 Progress and Upcoming 2026 Catalysts
-
The Simply Good Foods Company Reports Fiscal First Quarter 2026 Financial Results and Reaffirms Fiscal Year 2026 Outlook
-
Xali Gold Commences Work on Pico Machay Gold Project in Peru
-
Aronora Appoints Industry Leaders to Drive Next Phase of Growth
-
Enara Bio Enters 2026 with Dark Antigen Licensing to Boehringer Ingelheim, Appointment of Chief Medical Officer and Plans to Advance DARKFOX T-cell Engager into First-in-Human Studies
-
GlycoEra Appoints Petra Duda, M.D., Ph.D., as Chief Medical Officer to Advance Precision Immune Degrader Pipeline
-
Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGen
-
Tisento Therapeutics Completes Enrollment in PRIZM, a Global Phase 2b Study of Zagociguat for the Treatment of MELAS
-
Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference
-
Lantronix to Attend 28th Annual Needham Growth Conference on Jan. 13, 2026
-
Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2025 Revenue
-
AtaiBeckley Provides Update and Outlook for 2026 Ahead of J.P. Morgan Healthcare Conference
-
Aurora Mobile Congratulates Zhipu on Successful Hong Kong Listing
-
Brunswick Exploration Announces Inferred Mineral Resource of 52.2Mt at 1.08% Li2O at Mirage with Additional Exploration Target
-
Surge Copper Advances Berg Toward Pre-Feasibility with Successful 2025 Drilling and Data Validation Program
-
Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities
-
Woof Gang Achieves Record Growth in 2025
-
Anika Therapeutics Announces Leadership Transition
-
ONAR Completes Sale of Certain Legacy Assets in a Secured $1.5 Million Seller-Financed Transaction
-
Transpire Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference
-
Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026
-
Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones
-
Troilus Delivers on Key Development Milestones in 2025 and Enters a Pivotal Transition Year in 2026
-
Kinross to provide update on Round Mountain Phase X, Kettle River-Curlew and Bald Mountain Redbird 2 projects
-
Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases
-
AAVantgarde to Present at the 44th Annual J.P. Morgan Healthcare Conference
-
Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference
-
Fixing of coupon rates – Nykredit Realkredit A/S
-
Net Asset Value(s)
-
Enara Bio Enters 2026 with Dark Antigen Licensing to Boehringer Ingelheim, Appointment of Chief Medical Officer and Plans to Advance DARKFOX T-cell Engager into First-in-Human Studies
-
AccuStem Sciences Announces StemPrintER Pilot Study with National Surgical Adjuvant Breast and Bowel Project (NSABP)
-
Antag Therapeutics demonstrates compelling potential of its novel GIPR antagonist for obesity, reporting excellent tolerability in Phase 1 and enhanced weight loss in amylin combination study
-
CMR Surgical receives CE Mark for use of Versius in paediatric surgery
-
BitMEX Report Finds Crypto Perpetuals Enter Post-Yield Era
-
Indivior Provides Full-Year 2026 Financial Guidance and Business Update
-
Fury Reviews 2025 Achievements and Outlines 2026 Exploration Priorities
-
Lleida.net Begins 2026 With a 55.62% Increase in Clients Driven by Regulatory Demand
-
Endeavour Silver Produces 6,486,661 Oz Silver and 37,164 Oz Gold, for a total of 11.2 Million Silver Equivalent Oz in 2025
-
RentRedi Recognized for Premier Customer Service by National Association of Realtors®
-
Bridge Specialty Group acquires the assets of Shoemaker & Besser Associates, Inc.
-
Brookfield Asset Management to Host Fourth Quarter and Full Year 2025 Results Conference Call
-
Bridge Specialty Group acquires the assets of Shoemaker & Besser Associates, Inc.
